{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:27:22Z","timestamp":1789622842726,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>This study aims to determine prevalence and frequency of use of novel psychoactive substances (NPS) and to identify the factors associated with NPS use in an Italian sample of patients diagnosed with substance use disorder (SUD). Prevalence and correlates of NPS knowledge and use were assessed in 185 patients with SUD in three addiction services (Padova, Belluno, Feltre) in the Veneto region with an ad-hoc designed survey. Two thirds of the samples reported knowing NPS and one third reported using them. NPS were considered by them less dangerous than \u201cregular\u201d substances of abuse (t = 6.06 mean 0.78, p &lt; 0.001). Factors associated with NPS use were youth (OR = 4.81; p &lt; 0.001), studentship (OR = 4.99; p = 0.004), subsequent mental disorders diagnosis (OR = 2.49; p = 0.027), suicide attempt history (OR = 11.67; p &lt; 0.001), home detention (OR = 2.30; p = 0.040), residential care (OR = 5.66; p = 0.002), and polysubstance abuse (t = 8.99 mean 2.65 p &lt; 0.001). NPS use in patients with SUD is highly prevalent, particularly in the youngest age group, and associated with psychiatric comorbidity and worse prognosis. It is crucial to systematically assess NPS use and inform addiction service users with SUD of the toxic and potentially lethal side effects. Mental healthcare professionals working in addiction services should receive education and training. Cohort and longitudinal studies are needed.<\/jats:p>","DOI":"10.3390\/ijerph19020915","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T12:34:04Z","timestamp":1642163644000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Knowledge and Use of Novel Psychoactive Substances in an Italian Sample with Substance Use Disorders"],"prefix":"10.3390","volume":"19","author":[{"given":"Deborah","family":"Dal Farra","sequence":"first","affiliation":[{"name":"Department of General Psychology, University of Padua, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-3895","authenticated-orcid":false,"given":"Alice","family":"Valdesalici","sequence":"additional","affiliation":[{"name":"Department of General Psychology, University of Padua, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Zecchinato","sequence":"additional","affiliation":[{"name":"Addiction Department, AULSS 6 Euganea, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfio","family":"De Sandre","sequence":"additional","affiliation":[{"name":"Addiction Department, AULSS 1 Dolomiti, 32021 Agordo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Saccon","sequence":"additional","affiliation":[{"name":"Addiction Department, AULSS 4 Veneto Orientale, 30027 San Don\u00e0 di Piave, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Simonato","sequence":"additional","affiliation":[{"name":"Parco dei Tigli, 35037 Teolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-319X","authenticated-orcid":false,"given":"Ornella","family":"Corazza","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2341","authenticated-orcid":false,"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"},{"name":"Department of Neuroscience, Imaging, Clinical Sciences, University \u201cG.d\u2019Annunzio\u201d, 66100 Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Ottawa, Ottawa, ON K1N 6N5, Canada"},{"name":"Department of Mental Health, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Ottawa, Ottawa, ON K1N 6N5, Canada"},{"name":"Department of Mental Health, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"},{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(19)32231-7","article-title":"New psychoactive substances: Challenges for drug surveillance, control, and public health responses","volume":"394","author":"Peacock","year":"2019","journal-title":"Lancet"},{"key":"ref_2","first-page":"1","article-title":"Emerging Trends in Novel Psychoactive Substances and Health Consequences","volume":"1","author":"Kuypers","year":"2021","journal-title":"Emerg. Trends Drugs Addict. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"204512532096719","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: A review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"i6848","DOI":"10.1136\/bmj.i6848","article-title":"Novel psychoactive substances: Types, mechanisms of action, and effects","volume":"356","author":"Tracy","year":"2017","journal-title":"BMJ"},{"key":"ref_5","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2016). The Internet and Drug Markets, Publications Office of the European Union."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Langman, L.J., and Snozek, C.L.H. (2019). The Evolving Landscape of Designer Drugs. LC-MS in Drug Analysis. Methods in Molecular Biology, Humana Press.","DOI":"10.1007\/978-1-4939-8823-5"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hup.2300","article-title":"Novel Psychoactive Substances as a Novel Challenge for Health Professionals: Results from an Italian Survey","volume":"28","author":"Simonato","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_8","unstructured":"United Nations Office on Drugs and Crime (2021, August 24). Current NPS Threats. Volume III. Available online: https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_Threats_Vol.3.pdf."},{"key":"ref_9","unstructured":"European Monitoring Centre for Drugs and Drug Addiciton (2021). European Drug Report 2021: Trends and Developments, Publications Office of the European Union."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jfda.2017.04.001","article-title":"New psychoactive substances of natural origin: A brief review","volume":"25","author":"Feng","year":"2017","journal-title":"J. Food Drug Anal."},{"key":"ref_11","unstructured":"European Commission (2014). Flash Eurobarometer 401. Young People and Drugs Report, European Commission\u2014Directorate-General for Justice."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugpo.2017.11.003","article-title":"The diverse reasons for using Novel Psychoactive Substances\u2013A qualitative study of the users\u2019 own perspectives","volume":"52","author":"Soussan","year":"2018","journal-title":"Int. J. Drug Policy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2016.03.007","article-title":"The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations","volume":"32","author":"Soussan","year":"2016","journal-title":"Int. J. Drug Policy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fpsyt.2017.00110","article-title":"An expanding world of novel psychoactive substances: Opioids","volume":"8","author":"Zawilska","year":"2017","journal-title":"Front. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The Toxicology of Bath Salts: A Review of Synthetic Cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0b013e31828e1881","article-title":"The synthetic cannabinoid withdrawal syndrome","volume":"7","author":"Nacca","year":"2013","journal-title":"J. Addict. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1360-0443.2011.03719.x","article-title":"Cognitive and subjective effects of mephedrone and factors influencing use of a \u201cnew legal high\u201d","volume":"107","author":"Freeman","year":"2012","journal-title":"Addiction"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1521-0391.2012.00240.x","article-title":"\u201cSpice\u201d and \u201ck2\u201d herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans","volume":"21","author":"Gunderson","year":"2012","journal-title":"Am. J. Addict."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30036","DOI":"10.2807\/1560-7917.ES.2015.20.40.30036","article-title":"Injection of new psychoactive substance snow blow associated with recently acquired hiv infections among homeless people who inject drugs in dublin, ireland, 2015","volume":"20","author":"Giese","year":"2015","journal-title":"Eurosurveillance"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2016.11.006","article-title":"HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary\u2014An expanding public health burden","volume":"41","author":"Wiessing","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jemermed.2012.07.061","article-title":"Synthetic cannabinoid intoxication: A case series and review","volume":"44","author":"Harris","year":"2013","journal-title":"J. Emerg. Med."},{"key":"ref_23","unstructured":"Dipartimento per le Politiche Antidroga (2021, August 26). Relazione Annuale al Parlamento sul Fenomeno Delle Tossicodipendenze in Italia Anno 2021 (Dati 2020), Available online: https:\/\/www.politicheantidroga.gov.it\/media\/3076\/rap2021pdf.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"815424","DOI":"10.1155\/2014\/815424","article-title":"Novel psychoactive substances in young adults with and without psychiatric comorbidities","volume":"2014","author":"Martinotti","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/hup.2486","article-title":"Novel psychoactive substances: Use and knowledge among adolescents and young adults in urban and rural areas","volume":"30","author":"Martinotti","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00213-013-3188-4","article-title":"Spicing things up: Synthetic cannabinoids","volume":"228","author":"Spaderna","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1542\/peds.2011-1797","article-title":"Clinical Presentation of Intoxication Due to Synthetic Cannabinoids","volume":"129","author":"Cohen","year":"2012","journal-title":"Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/15563650.2011.609822","article-title":"Severe toxicity following synthetic cannabinoid ingestion","volume":"49","author":"Lapoint","year":"2011","journal-title":"Clin. Toxicol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2013.06.016","article-title":"Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports","volume":"132","author":"Miotto","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1360-0443.2011.03502.x","article-title":"Mephedrone: Use, subjective effects and health risks","volume":"106","author":"Winstock","year":"2011","journal-title":"Addiction"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lfs.2013.10.033","article-title":"Behavioral pharmacology of designer cathinones: A review of the preclinical literature","volume":"97","author":"Gregg","year":"2014","journal-title":"Life Sci."},{"key":"ref_32","first-page":"10","article-title":"Bath salts-induced psychosis: A case report","volume":"10","author":"Mangewala","year":"2013","journal-title":"Innov. Clin. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00228-012-1361-z","article-title":"First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam","volume":"69","author":"Dargan","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive Effects of Long-Term Benzodiazepine Use","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/15563650.2014.983239","article-title":"Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45","volume":"53","author":"Siddiqi","year":"2015","journal-title":"Clin. Toxicol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/15563650.2015.1054505","article-title":"Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project","volume":"53","author":"Beck","year":"2015","journal-title":"Clin. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FBP.0000000000000241","article-title":"Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: A review of case reports and preclinical findings","volume":"27","author":"Zanda","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3109\/15563650.2012.683437","article-title":"Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation","volume":"50","author":"Shields","year":"2012","journal-title":"Clin. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjd.18108","article-title":"Suicidality and risk of suicidality in psoriasis: A critical appraisal of two systematic reviews and meta-analyses","volume":"181","author":"Matterne","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2012.05.022","article-title":"The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review","volume":"39","author":"Corkery","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/15563650.2013.802795","article-title":"Severe clinical toxicity associated with analytically confirmed recreational use of 25I\u2013NBOMe: Case series","volume":"51","author":"Hill","year":"2013","journal-title":"Clin. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/15563650.2015.1004179","article-title":"Prevalence of use and acute toxicity associated with the use of NBOMe drugs","volume":"53","author":"Wood","year":"2015","journal-title":"Clin. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13181-013-0287-x","article-title":"Recurrent Seizures and Serotonin Syndrome Following \u201c2C-I\u201d Ingestion","volume":"9","author":"Bosak","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"ref_44","first-page":"137","article-title":"Chemistry, pharmacology, and toxicology of khat (catha edulis forsk): A review","volume":"3","author":"Wabe","year":"2011","journal-title":"Addict. Heal"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"van den Harm potential of magic mushroom use: A review","volume":"59","author":"Opperhuizen","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5507\/bp.2004.002","article-title":"Khat habit and its health effect. A natural amphetamine","volume":"148","author":"Dhaifalah","year":"2004","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107508","DOI":"10.1016\/j.drugalcdep.2019.06.011","article-title":"Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012\u20132017)","volume":"204","author":"Larabi","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fpsyt.2020.00569","article-title":"Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment","volume":"11","author":"Specka","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.drugalcdep.2014.07.009","article-title":"Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates","volume":"143","author":"Bonar","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hup.2512","article-title":"New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening","volume":"31","author":"Heikman","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: A postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fpsyt.2020.00879","article-title":"Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients","volume":"11","author":"Martinotti","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Martinotti, G., Merino Del Villar, C., Garcia Cordoba, A., Andr\u00e9s Tubau, L., Castro S\u00e1nchez, I., Di Carlo, F., Chiappini, S., Pettorruso, M., Schifano, F., and Di Giannantonio, M. (2021). Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18136944"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113638","DOI":"10.1016\/j.expneurol.2021.113638","article-title":"New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review","volume":"339","author":"Schifano","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_55","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2018). New Psychoactive Substances in Prison, Publications Office of the European Union."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2009.02.002","article-title":"\u201cThey\u2019re legal so they\u2019re safe, right?\u201d What did the legal status of BZP-party pills mean to young people in New Zealand?","volume":"21","author":"Sheridan","year":"2010","journal-title":"Int. J. Drug Policy"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/2\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:27:22Z","timestamp":1760362042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/2\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijerph19020915"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19020915","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]}}}